Entera Bio (ENTX) Proxy filing summary

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 Annual Meeting.

• Approval of amended compensation terms for non-executive directors.

• Approval of share-based compensation for two directors and the Chairman.

• Approval of one-time compensation grants for two directors, including the CEO.

• Amendment to the 2018 Equity Incentive Plan to increase shares issuable by 2,500,000.

• Amendment to the Articles of Association to increase authorized share capital.

• Advisory, non-binding vote on executive officer compensation.

• Appointment of PwC as independent auditors for fiscal year ending December 31, 2026, with authorization to set auditor compensation.

Board of directors and corporate governance

• Board recommends a vote in favor of all ten proposals.

• Annual meeting scheduled for July 14, 2026, in Jerusalem, Israel.

Executive compensation and say-on-pay

• Proposals include approval of amended and one-time compensation for directors and CEO.

• Advisory vote on executive compensation, including tables and narrative discussion.